FDAnews
www.fdanews.com/articles/147500-ventrus-implodes-on-drug-study

Ventrus Implodes on Drug Study

June 26, 2012
Shares of Ventrus Biosciences plunged after the biotech group said that a Phase III clinical trial for its drug iferanserin, or VEN 309, failed to show it was effective in treating hemorrhoidal disease. Ventrus said while it intends to review the study, it believes it will cease development of VEN 309 and instead focus its resources on its VEN 307 and VEN 308 development programs.
MarketWatch